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Journal of Stroke and CerWe report the case of a 35-year-old male with COVID-19 encephalitis presenting as
a stroke mimic with sudden-onset expressive and receptive dysphasia, mild confu-
sion and right arm incoordination. The patient received thrombolysis for a sus-
pected ischaemic stroke, but later became febrile and SARS-CoV-2 was detected in
cerebrospinal fluid. Electroencephalography demonstrated excess in slow waves,
but neuroimaging was reported as normal. Respiratory symptoms were absent
throughout and nasopharyngeal swab was negative for SARS-CoV-2. At the most
recent follow-up, the patient had made a full neurological recovery. Clinicians
should therefore consider testing for SARS-CoV-2 in CSF in patients who present
with acute focal neurology, confusion and fever during the pandemic, even when
there is no evidence of respiratory infection.
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The neurological complications associated with
COVID-19 remain under investigation, with cerebrovas-
cular disease at the forefront of debate.1 This case demon-
strates the complexities faced characterising neurological
pathology during the SARS-CoV-2 pandemic, with real-
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A 35-year-old male presented with sudden-onset
expressive and receptive dysphasia, mild confusion and
right arm incoordination (National Institutes of Health
Stroke Scale: 5). The patient had a medical history of
migraines only, no regular medication and was a current
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Fig. 1. A) Day 1 CT Brain  Normal; B) Day 2 CT Brain- Normal, standard 24-hour post thrombolysis imaging; Day 3 MRI Head T2 (C) and FLAIR (D) 
Normal; E) Day 5 MRA Head - normal with congenitally hypoplastic left A1 segment anterior cerebral artery- marked on image (incidental finding) (TOF
image); F) Day 25 MRI Head T2 (F) and FLAIR (G) Normal.
2 D. GLAVIN ET AL.intracranial abnormalities and the patient received throm-
bolysis for a suspected ischaemic stroke. Symptoms
resolved over 2 hours and post-thrombolysis CT (day 2,
Fig. 1B) was reported as normal. Respiratory symptoms
were absent, and admission nasopharyngeal swab was
negative for SARS-CoV-2.
On day 3, the patient had right arm weakness and later
developed expressive and receptive dysphasia, amnesia,
headache and vomiting, followed by pyrexia 39.7°C. GCS
remained 15/15 without evidence of meningism. MRI
brain (day 3, Fig. 1C,D) was normal.
Lumbar puncture (day 4) had an opening pressure
24cm/H2O with clear CSF, white cell count 134 £ 106/L
(99% lymphocytes), red cell count 20 £ 106/L, protein
0.52g/L and CSF:serum glucose ratio 3.7:5.1mmol/L
(0.73). CSF culture was negative and polymerase chain
reaction (PCR) negative for Neisseria meningitides, Strepto-
coccus pneumoniae and several viruses including HSV, vari-
cella zoster virus, enterovirus and parechovirus. However,
PCR of the CSF was positive for SARS-CoV-2 RNA, with
identification of both the E gene (CT value 35.8) and S gene
(CT value 35.7) (Altona RealStar SARS-CoV-2 RT-PCR Kit,
Roche Flow system). MR angiogram brain (day 5, Fig. 1E)
showed incidental congenitally hypoplastic left A1 seg-
ment of anterior cerebral artery. Pyrexia and amnesia per-
sisted, but by day 8, the patient was deemed to have made
a full recovery and discharged.Follow-up MRI brain (day 25, Fig. 1F,G) was normal,
and electroencephalography (day 34) demonstrated gen-
eralized slowing suggestive of encephalopathy, which
was not otherwise explained. At outpatient follow-up
(day 55), there were no ongoing neurological symptoms.
Serum antibody testing did not detect anti-SARS-CoV-2
antibodies.Discussion
The differentiation of strokes and stroke mimics is a
particular challenge in COVID-19 patients. Limited stroke
risk factors, new seizures, acute or subacute encephalopa-
thy and reduced GCS could suggest a stroke mimic.1
Whilst several reports have speculated upon the diag-
nosis of encephalitis in COVID-19 patients,2-4 detection of
SARS-CoV-2 in CSF remains rare.5-7 Two main plausible
routes of entry for SARS-CoV-2 to the central nervous sys-
tem (CNS) are via the angiotensin-converting enzyme 2
receptors located on epithelial cells of the blood-cerebro-
spinal fluid barrier and via retrograde axonal transport of
peripheral neural pathways such as via the olfactory
mucosa in the nasal cavity.8
Evidence of CSF pleocytosis with white cell count
>100 £ 106/L is suggestive of CNS infection and is clear
evidence of CSF inflammation.9 Numerous other CNS
and systemic infections were excluded on culture and
COVID-19 ENCEPHALITIS: POTENTIAL STROKE MIMIC 3PCR. Non- infectious causes were excluded with brain
imaging (CT, MRI and MRA brain). There are several
potential reasons for negative nasopharyngeal PCR tests
including reduced viral load, transient viral dissemination
or collection and storage errors. Research has shown a
median false negative rate of COVID-19 nasopharyngeal
RT-PCR of 38% on the day of symptom onset and maxi-
mum COVID-19 replication in the throat seen 5 days after
symptom onset.10-11
Clinicians should therefore consider testing for SARS-
CoV-2 in CSF in patients who present with acute focal
neurology, confusion and fever during the pandemic,
even when there is no evidence of respiratory infection.
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